Company News

首页 - 关于我们 董事会

董事:邵辉

邵辉博士自2020年12月起担任本公司董事兼首席执行官,现任本公司董事、副董事长兼首席商务官。在此之前,邵博士于 2018 年 2 月至 2020 年 12 月担任依生生物(湖岸生物前身)的董事、总裁及首席执行官,并自 2010 年 10 月起担任该公司的首席财务官及全球业务负责人。此外,邵博士于 2007 年 1 月至 2010 年 10 月担任 Axing Pharmaceutical Company, Inc. 的高级财务副总裁及首席财务官,负责根据美国公认会计准则(GAAP)及美国证券交易委员会(SEC)的相关规则与法规编制财务报表。2005 年至 2007 年,邵博士在纽约 Kamting Street Capital Management 担任高级生物技术分析师;2003 年至 2005 年,于纽约 Mehta Partners 担任医疗保健分析师。在此之前,邵博士在美国罗氏制药(Roche Pharmaceuticals)担任首席科学家达五年之久。


邵博士于 1991 年获中国科技大学化学学士学位,于 1996 年获美国加州大学圣地亚哥分校生物有机化学博士学位,于 2003 年获纽约大学斯特恩商学院金融与会计硕士学位。此外,邵博士是特许金融分析师(CFA)持证人,并持有美国注册会计师协会(AICPA)颁发的专业资格证书。


Director, Vice Chairman of the Board and Chief Business Officer

Dr. Hui Shao has served as our director and chief executive officer since December 2020, currently acting as our director, vice chairman of the board and chief business officer. Dr. Shao served as the director, president and chief executive officer of Yisheng Biopharma from February 2018 to December 2020, and prior to that, had served as the chief financial officer and global business head of the same company since October 2010. Dr. Shao served as the senior vice president of finance and then the chief financial officer of Aoxing Pharmaceutical Company, Inc. from January 2007 to October 2010, where he was responsible for preparing financial statements in accordance with U.S. GAAP and SEC rules and regulations. From 2005 to 2007, Dr. Shao was a senior biotechnology analyst at Kamunting Street Capital Management in New York. From 2003 to 2005, Dr. Shao was a healthcare analyst at Mehta Partners in New York. Prior to that, Dr. Shao had spent five years as a principal scientist at Roche Pharmaceuticals, USA.


Dr. Shao received his bachelor’s degree in chemistry from University of Science and Technology of China in 1991, his Ph.D. degree in bioorganic chemistry from University of California, San Diego in 1996, and an M.B.A. degree in finance and accounting from Stern School of Business, New York University in 2003. Dr. Shao is a chartered financial analyst (CFA) and an AICPA holder in the State of Washington, the United States.